Congress has the power to make obesity treatment and weight management accessible to the communities that need it.

With foodborne illnesses and changes in Medicare and Medicaid coverage, University of Virginia (UVA) Health experts say never ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Industry experts ...

Medicare Part D will cover popular weight loss drugs like Wegovy and Ozempic starting in 2026, with copays capped at $50 per ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

Starting Jan. 1, New Hampshire’s Medicaid program will stop covering GLP-1 drugs — Wegovy, Zepbound, and others — for weight ...

The Alliance for Women’s Health and Prevention wrote a letter to Gov. Ayotte urging her to reconsider the decision. The organization noted that approximately 30% of women in New Hampshire experience ...

Last month’s deal with the US government has also brought forward regulatory approval and commercialisation timelines, with ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for ...